Evidence map›Paper›PMID 30934797›Full record

Trial reportNutrients2019

Effect of PolyGlycopleX (PGX) Consumption on Blood Lipid Profiles in Healthy, Low CVD Risk Overweight Adults.

Vicky A Solah, Deborah A Kerr, Deasy Irawati, Wendy Hunt, Xingqiong Meng, Roland J Gahler, Haelee K Fenton, Stuart K Johnson, Anthony P James, Simon Wood

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrients, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Vicky A SolahSchool of Molecular and Life Sciences, Faculty of Science and Engineering, Curtin University, Perth, WA 6845, Australia. v.solah@curtin.edu.au.
Deborah A KerrSchool of Public Health, Faculty of Health Sciences, Curtin University, Perth, WA 6845, Australia. d.kerr@curtin.edu.au.ORCID 0000-0002-1094-1299
Deasy IrawatiSchool of Public Health, Faculty of Health Sciences, Curtin University, Perth, WA 6845, Australia. deasy15ira@yahoo.com.
Wendy HuntSchool of Public Health, Faculty of Health Sciences, Curtin University, Perth, WA 6845, Australia. Wendy.Hunt@aegic.org.au.
Xingqiong MengFlinders Centre for Epidemiology and Biostatistics, College of Medicine and Public Health, Flinders University, Adelaide, SA 5001, Australia. Rosie.Meng@sa.gov.au.
Roland J GahlerFactors Group R & D, Burnaby, BC V3N4S9, Canada. rgahler@naturalfactors.com.
Haelee K FentonSchool of Molecular and Life Sciences, Faculty of Science and Engineering, Curtin University, Perth, WA 6845, Australia. h.fenton@curtin.edu.au.
Stuart K JohnsonSchool of Molecular and Life Sciences, Faculty of Science and Engineering, Curtin University, Perth, WA 6845, Australia. s.johnson@curtin.edu.au.
Anthony P JamesSchool of Public Health, Faculty of Health Sciences, Curtin University, Perth, WA 6845, Australia. T.P.James@curtin.edu.au.
Simon WoodSchool of Public Health, Faculty of Health Sciences, Curtin University, Perth, WA 6845, Australia. simonwood@shaw.ca.
Curtin University · AUFlinders University · AUUniversity of British Columbia · CA

Funding

Factors Group, Australia Pty Ltd 6397
6 · The paper itself

Abstract

Raised blood lipid levels are associated with a risk of a cardiovascular disease (CVD). Moderate reductions in several CVD factors such as total, low-density lipoprotein (LDL) cholesterol and non-high-density lipoprotein (non-HDL) cholesterol concentrations may be more effective in reducing overall risk than a major reduction in just one. A blind, randomised controlled trial was conducted with 120 healthy overweight (BMI 25⁻30) adults aged 25⁻70 years who were non-smokers, not diabetic and of low risk of cardiovascular disease, as assessed by the Framingham risk equation. Participants consumed 4.5 g PolyGlycopleX (PGX) as softgel capsules (PGXS) or 5 g PGX granules (PGXG) or 5 g rice flour (RF) with meals three times a day for 12 weeks. Total, LDL and non-HDL cholesterol were all significantly reduced (-6%, -5% and -3.5%, respectively) post the PGX granule treatment; however, PGX in softgel capsule form did not affect blood lipid profiles. Daily consumption of PGX granules in overweight low CVD risk adults produced lipid changes indicating a CVD preventative benefit.

Indexed as

Dietary SupplementsAdultAgedAlginatesCardiovascular DiseasesCholesterolCholesterol, LDLDrug CombinationsFemaleHumansLipidsMaleMiddle AgedOverweightPolysaccharides, BacterialRisk FactorsAlginatesCholesterolCholesterol, LDLDrug CombinationsLipidsPolyGlycoplexPolysaccharides, Bacterialblood lipidscardiovascularcholesteroldisease risk

Identifiers

PMID30934797
PMCPMC6520870
OpenAlexW2923617071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.